Record · corpus.blog/posts/01a0f576-b8a4-72cc-b1d6-42a58ddd63dd
Sasanlimab as bladder-sparing maintenance treatment after neoadjuvant chemotherapy in patients with muscle invasive bladder cancer (MIBC): The phase 2, SASAN-SPARING trial.
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs · 30 September 2026 · 2 min read
A post on inventcures.github.io, published 30 September 2026, has not been cited by any blog yet (corpus.blog, measured 9 October 2026).
A record is what was published and who pointed at it. The text of the post is not held here: read it at the source, or at its Wayback capture.
0blogs citing
| Period | Blogs | Links |
|---|---|---|
| All time | 0 | 0 |
| Last 90 days | 0 | 0 |
| Last 30 days | 0 | 0 |
| Last 7 days | 0 | 0 |
| Anchor phrases | 0 |
|---|---|
| External links | 0 |
| Words captured | 377 |
Cited by
No blog we hold has cited this post yet.
Links from this post
This post doesn't link to any pages we've captured.
Similar posts
Comparing Bladder Cancer Treatment Options
verywellhealth.com
18 Sept 2026
Something wrong here? Report a problem